Related references
Note: Only part of the references are listed.Assessing the measure of a new drug: Is survival the only thing that matters?
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer
Tomasz Burzykowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer
Kathy Miller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
End points for colon cancer adjuvant trials: Observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 Randomized trials from the ACCENT group
Daniel J. Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Surrogate end points for median overall survival in metastatic colorectal cancer: Literature-based analysis from 39 Randomized controlled trials of first-line chemotherapy
Patricia A. Tang et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Endpoints for agents that slow tumor growth
Ron X. Yu et al.
CONTEMPORARY CLINICAL TRIALS (2007)
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer
Alessandra Gennari et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18 randomized trials
DJ Sargent et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer
A Hackshaw et al.
BRITISH JOURNAL OF CANCER (2005)
Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute Trial AB01
RE Langley et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Survival of metastatic breast carcinoma patients over a 20-year period - A retrospective analysis based on individual patient data from six consecutive studies
A Gennari et al.
CANCER (2005)
Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer
SE Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A systematic review of taxane-containing regimens for metastatic breast cancer
D Ghersi et al.
BRITISH JOURNAL OF CANCER (2005)
Gemcitabine, epirubicin, and paclitaxel versus fluorouracil, epirubicin, and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: A central European cooperative oncology group international, multicenter, prospective, randomized phase III trial
C Zielinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Surrogate endpoints and FDA's accelerated approval process
TR Fleming
HEALTH AFFAIRS (2005)
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: Cancer and Leukemia Group B Trial 9342
EP Winer et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The validation of surrogate end points by using data from randomized clinical trials: a case-study in advanced colorectal cancer
T Burzykowski et al.
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES A-STATISTICS IN SOCIETY (2004)
CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment
A Trotti et al.
SEMINARS IN RADIATION ONCOLOGY (2003)
Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer
A Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III study of cyclophosphamide, doxorubicin, and fluorouracil (CAF) plus leucovorin versus CAF for metastatic breast cancer: Cancer and Leukemia Group B 9140
HL Parnes et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193)
GW Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 multicenter phase III trial
L Biganzoli et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
The influence of handling censored data on estimating progression-free survival in cancer clinical trials (JCOG9913-A)
M Niimi et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2002)
Considerations in the evaluation of surrogate endpoints in clinical trials: Summary of a National Institutes of Health Workshop
VG De Gruttola et al.
CONTROLLED CLINICAL TRIALS (2001)
Results of a phase III prospective, randomised trial, comparing mitoxantrone and vinorelbine (MV) in combination with standard FAC/FEC in front-line therapy of metastatic breast cancer
M Namer et al.
EUROPEAN JOURNAL OF CANCER (2001)
The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomized trials
D Moher et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Accelerated-intensified cyclophosphamide, epirubicin, and fluorouracil (CEF) compared with standard CEF in metastatic breast cancer patients: Results of a multicenter, randomized phase III study of the Italian Gruppo Oncologico Nord-Ouest-Mammella Inter Gruppo Group
L Del Mastro et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial
J Jassem et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: A randomized multinational study
SP Ackland et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: A European organization for research and treatment of cancer randomized study with cross-over
R Paridaens et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Comparison of chemotherapy with chemohormonal therapy as first-line therapy-for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study
GW Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
